Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes

Clinical trial NCT06390748 · COMPLETED

Trial details

NCT number: NCT06390748
Sponsor: Lin Chen
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Sepsis Lymphocyte Disorder T Immunologic Paralysis Catecholamine; Overproduction Beta-Blocker Cytokine Storm Sympathetic Nervous System Diseases

Start date: 2021-01-01
Primary completion: 2023-12-31
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.